The Use of Dexmedetomidine for EEG Sedation in Children With Behavioural Disorders
Status:
Completed
Trial end date:
2019-09-28
Target enrollment:
Participant gender:
Summary
Children's compliance during diagnostic or therapeutic procedures is a challenge, often
requiring the use of sedative and/or analgesic drugs.
Electroencephalogram (EEG) needs stillness for a medium-long period but, at the same time,
the use of any drug for sedation may affect the exam through an interference with EEG waves.
Dexmedetomidine is a selective ∝2-adrenergic agonist with sedative and anxiolytic properties,
with a long effect and which does not alter EEG pattern.
The aim of this interventional study is to evaluate the effectiveness, safety and feasibility
of dexmedetomidine for sedation during EEG in children who are not cooperative.
Children affected by behavioral disorders and requiring sedation to perform EEG were
considered. The protocol establishes to administer IV dexmedetomidine (loading dose and
continued infusion) to reach a targeted level of sedation (Pediatric Sedation State Scale =
2). Vital signs (SatO2, RR, EtCO2, HR, BP) and level of sedation are recorded before, during
and after procedure until the offset.